Minoryx Preps For Tough Pricing Regime As CNS Orphan Drug Enters Phase II/III

 
• By Lucie Ellis-Taitt
  
Hurdles
Minoryx will face value as well as efficacy hurdles

More from Rare Diseases

More from Scrip